StemCell Therapy

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/genome-editing-services-world-markets-to-2030-focus-on-crispr---the-most-popular-genome-manipulation-technology-tool-300966100.html

SOURCE Research and Markets

Excerpt from:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community

Appiah rang Leukaemia Cares helpline from the point of diagnosis until well after the end of her daughters life. Sometimes Id call them as a means of support, she says, when things got really rough, when her medications were really powerful, and the chemo made her so unwell. She rang when she had panic attacks; an NHS psychologist had told her that these were likely, and that she should breathe into a brown paper bag, but Appiah found speaking to a person more soothing.

With a laugh, Appiah notes that shed ring the helpline at other times, too: Sometimes Id be out with Imogin, and shed be in the pram, being naughty, and all of my patience was going down the drain, and Id phone Leukaemia Cares nurses, and say: Look, Im feeling so depressed, my daughters shouting, I dont know what to do!

But I might also say: Nurse, Im actually feeling good today.

Appiah says the support of an independent person was invaluable: When your child is so ill, you need to speak to someone who doesnt know your name you need an outsider you can unload to. I didnt want anyone thinking: Here Sheila comes again!

You become self-conscious about your situation and dont want to be a burden on your friends and family. With the helpline, you wont be judged: they just listen. You get it out of your system and then go do the shopping at Sainsburys.

When Imogin was well, shed go to school. But she also spent weeks at a time in isolation in St Georges Hospital, with her mother by her side. Once, she had a bad reaction to a medication and went into cardiac arrest. She was crying and saying, Please, please! and they were giving her all sorts of medicine. The doctors were battling to keep her stable and I dived into the bed with her and told her: Youre going to be OK. I lay down with her and I started singing with her. And then, once she stabilised, she said: Now can I watch High School Musical?"

Appiah shakes her head, laughing: Thats what she was like: I was on thedoor of death, but I have something else planned. I want to watch my video and none of you are going to stop me!

Charities sent the pair to Disneyland Paris twice. The first time was fantastic, says Appiah, the second time Imogin was in and out of consciousness. But they said we should go, to make memories, Appiah explains. Imogin got to be a celebrity for a day and went to Hamleys in a limousine to get anything she wanted.

See the original post:
'My daughter's death took me to the darkest place, but I've learned it's possible to come back' - Telegraph.co.uk

GammaDelta Therapeutics is a company that focusses on utilizing the unique properties of gamma delta () T cells to develop novel immunotherapies for patients.Through their research, the companys scientists have discovered a number of targets and antibodies that have the potential to modulate the activity of T-cells in situ. Therefore, GammaDelta Therapeutics recently announced the formation of Adaptate Biotherapeutics, a spin-out company that will focus on research in this area.

Technology Networks spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Molly Campbell (MC) Please can you tell us more about T-cell based cell therapy products and their potential applications?Natalie Mount (NM): T cells play an increasingly appreciated critical role in immune surveillance, being able to recognize malignant/transformed cells through a pattern of stress markers. The recognition mechanism is not major histocompatibility complex (MHC) restricted and not dependent on a single antigen.

T cells therefore have potential in a range of disease indications, including both hematological and solid malignancies and a positive correlation between T cell infiltration and prognosis/survival in patients has been determined in a range of oncology indications in studies published in the literature by other groups. Additionally, as a cell therapy, T cells can be used in an allogeneic setting (ie, T cells can be used for unrelated recipients without a requirement for matching).

Both Adaptate Biotherapeutics and GammaDelta Therapeutics are focussed on harnessing the potential of T cells, in particular the V1 subtype which is the predominant T cell type in tissue.This is based on data originating from the labs of Professor Adrian Hayday of Kings College London and the Crick Institute, supported by Cancer Research Technology and also from Professor Bruno Silva Santos of Institute for Molecular Medicine at the University of Lisbon, Portugal.

Previous clinical trials conducted by other groups/companies targeting or using T cells in cancer have focussed on the V2 subtype which is predominant in the blood. These trials have demonstrated safety, but efficacy has been limited.Compared to V2 cells, V1 cells, which are the focus of work at Adaptate Biotherapeutics and GammaDelta Therapeutics, are less susceptible to exhaustion and activation induced cell death. Expansion of donor derived V1 has been shown to be a positive prognostic indicator for acute myeloid leukemia patients following hematopoietic stem cell transplant.

MC: Why are current immunotherapy treatment approaches limited?NM: Immunotherapy approaches have had very significant success and impact in Oncology recently, however, challenges and unmet needs remain.One challenge is effective treatment of solid tumors. The hypoxic, low nutrient tumor environment provides a challenge for successful infiltration and activation of T cells. However, V1 T cells have real potential as they are naturally tissue resident and hence primed for this environment. In addition, their ability to recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than one specific antigen presented by the MHC provides an additional advantage for both specificity of response and maintenance of efficacy.

T cells act as orchestrators of an immune response and, following recognition of a cell as malignant, they induce maturation of monocytes and signal to alpha beta T cells, hence increasing immunogenicity of the tumor and providing a sustained response, with potential even in tumors with low mutational load which have proven challenging with other immunotherapies.

MC: The new spin-out company, Adaptate Biotherapeutics, will build on GammaDelta's knowledge to modulate T-cell activity using therapeutic antibodies. Why have you decided to create a spin-out focusing on this area of research?NM: GammaDelta Therapeutics was formed in 2016 to harness the unique properties of T cells, and since then has gained extensive knowledge of T-cell biology. In addition to gaining insight into cell growth and isolation, the companys scientists have also discovered a number of targets and antibodies that have potential to modulate the activity of T-cells in situ.

GammaDelta Therapeutics now has a pipeline of cell therapy products progressing into clinical development under the guidance of CEO, Dr Paolo Paoletti.

Adaptate Biotherapeutics will be developing antibodies which will be administered to cancer patients to modulate activity of the patient's gamma delta T cells in situ.

Delivery of cell therapy and antibody therapeutics each needs focus and specific skillsets and formation of two independent entities will facilitate this. The two companies share a common goal to harness the potential of T cells to bring effective therapies to patients. Both benefit from support of the scientific founding team and have common investors, Abingworth and Takeda Pharmaceuticals.MC; Your goal is to develop targets and antibodies that can modulate the activity of T-cells and advance them into clinical studies. What challenges exist here, and how do you hope to overcome them?

Our assets at Adaptate Biotherapeutics are currently at the pre-clinical stage and therefore face the non-clinical development risks for a novel therapy. However, these risks are mitigated by biology understanding from our scientific founders and the work at GammaDelta Therapeutics to date.

One of our challenges is in selecting the most suitable patient population for initial trials. There is potential for opportunity for our therapeutics in multiple indications but the utility of animal models in modelling the human immune compartment and human tumor setting is limited. Therefore in vitro and ex vivo models are important, in addition to the learnings from other clinical studies.

MC: GammaDelta Therapeutics formed in 2016 to gain extensive knowledge of T-cell biology and to developing a portfolio of investigational cell therapies. Some of these cell therapies are poised to enter clinical development. Can you tell us any further information about these therapies?NM: GammaDelta was set up to develop cell-based therapy utilizing ex-vivo expanded tissue resident gd T cells. Subsequent acquisition of Lymphact SAS allowed GammaDelta to augment its capabilities with a platform for ex-vivo expansion of blood derived V1 cells. GammaDelta is focussed on progressing ex-vivo expanded skin and blood derived V1 cells to the clinic both in unengineered and engineered formats. Clinical trials are currently on track to commence in the next 12-18 months.

MC: Your press release states: "The two companies will continue sharing their insights into T-cell biology as they work towards developing different therapeutic modalities". How will you continue to share insights here?NM: Antibodies and cells represent complementary approaches to realizing the potential of T cell activity for patients with solid and haematological malignancies.

The two companies will work together in areas of common interest in the biology of these fascinating cells, such as understanding the phenotype and behavior of T cells in tumors and mechanisms of cell regulation as well as the effects of antibody on the T cells.

We have deliberately established a contractual framework that allows efficient collaboration between scientists of both the companies via formal and informal meetings.

MC: What are your hopes for the future of Adaptate Biotherapeutics?NM: This is a remarkable time in the development of new immune therapies, and the role of "non-conventional" cell types of the immune system is coming to the fore as we recognize the successes achieved to date and the needs of patients and related scientific challenges that remain.

Both GammaDelta Therapeutics and Adaptate Biotherapeutics are at the lead of translating our increasing understanding of T cell biology and its potential into therapies to address these unmet needs.

Adaptate Biotherapeutics has a fantastic opportunity to build and accelerate a portfolio of antibody-based approaches in this novel area and I look forward to the successful translation of this science into therapies with the support of our investors at Abingworth and Takeda Pharmaceuticals.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics was speaking with Molly Campbell, Science Writer, Technology Networks.

Read more here:
Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks

Bradley J. Fikes, an ever-on-the move ball of energy who roamed the labs of San Diego as the Union-Tribunes biotech writer, chronicling scientists efforts to find ways to alleviate human suffering, died on Wednesday. He was 61.

His family said he passed away of natural causes at his home in Grantville. He had been dividing his time between poring through medical journals and exploring his two other great loves, the San Diego Zoo and Safari Park in Escondido.

Fikes who was part Dr. Dolittle, part Inspector Gadget was especially excited earlier this week as he pulled together a story about two extremely rare platypuses that are being introduced at the zoo.

He talked about it almost non-stop as we drove back and forth between the zoo, said Michelle Guerrero, a Union-Tribune illustrator and graphics reporter. He knew how animals evolve, their relationship with humans, and how they ended up at zoos.

He had the wonderment of a child, the complexity of a scientist and an artful way of coming up with the words to explain it all.

This is the last known photograph of Bradley J. Fikes, the Union-Tribunes biotech writer

(Howard Lipin/The San Diego Union-Tribune)

Fikes was forever in the middle of things, in a literal and figurative sense.

Every Friday, he staked out a table at Bella Vista, a heavily-trafficked cafe between the Salk Institute and UC San Diego. In science, anybody whos anybody and everybody who wants to become somebody hangs out at Bella and networks.

Fikes listened in, took notes, then speed-wrote stories that were devoured by the biotech brigade. Fikes could talk non-stop for 30 minutes about the nature of pluripotent stem cells, then do another half-hour on telomeres and wrap up with some thoughts on chimeras.

He also hung at Bella because of the food. He loved the comfort fare. He loved it so much that Bellas owner, Amanda Caniglia, named a spaghetti dish after him. She called it Il Journalista.

Fikes was impossible to miss. By his own admission, he was a walking fashion disaster. He wore odd-colored business shirts that clashed with his suspenders, and slacks that never made contact with an iron. At times, cellphone cables hung out of his pockets like limp licorice. He feared not having enough power to use his cellphone to watch Black Sabbath and Van Halen videos on YouTube.

People lovingly teased him, hoping for a retort. He often snapped his own suspenders, smiled, and asked, Are you jealous?

News of his death elicited a wave of sorrow and praise Thursday from the countys science industry, whose denizens knew Fikes as a deliciously quirky figure who understood the arcane language of science and the people who are drawn to it.

I always prepped scientists who were meeting him for the first time not to be fooled by the red suspenders and taped glasses, said Chris Emery, communications director at Scripps Research in La Jolla. Bradley is the most legit science reporter youll encounter.

Fikes also was lauded for highlighting the needs and interests of patients, particularly Theresa Blanda and Nancy Davidson, a pair of Orange County women who suffered from debilitating blood cancers.

He followed their cases closely as they sought experimental drugs that might keep them alive. Blanda also supported the biotech companies who were willing to pursue fresh alternatives, even though the outlook was grim.

Blanda later died. But UC San Diego cancer specialist Catriona Jamieson, who helped with the womens treatment, said Fikes was invaluable in telling their stories.

Bradley championed their cause by telling their stories clearly, said Jamieson. He was a serious advocate for patients. He persevered and got difficult stories right. Ive always been a big fan of Bradley.

He was also very keen on gender diversity in life science, said Dawn Barry, president and co-founder of LunaDNA. We lost such a warm, engaged, important San Diego citizen.

Bradley Joseph Fikes was born in San Diego on Jan. 30, 1958, the son of Garland Fikes, a blueprinter, and Trudy Fikes, a nurse who worked at Mercy Hospital.

He learned to read and comprehend difficult information early, which led to a life-shaping moment when he was roughly 6 years old.

Fikes discovered a medical encyclopedia that captivated his attention. One afternoon, he shared the book with neighborhood children, which alarmed their parents because it showed explicit images of the human body.

It was just anatomy; there was nothing wrong with it, said Vanessa Dimalanta, one of Fikes three sisters. That was Brad. Always reading, always sharing with others.

His obsession with science deepened while he was attending San Diego High School and it grew at San Diego State University, where he found his calling journalism.

Like hundreds before him, Fikes joined the Daily Aztec, the campus newspaper, which operated in a raucous newsroom that had male mannequin legs hanging from the ceiling.

This is where he found his tribe, said Karla Peterson, a Union-Tribune columnist who also was part of the Aztec staff.

He loved the work and was at it all of the time. He had so much energy. When we threw parties, Bradley was always the first to arrive and the last to leave. He was happy. He knew how to enjoy life.

Union-Tribune theater critic James Hebert said, He struck me as a total original from the moment I met him like our own slightly mellower answer to Hunter S. Thompson. And it was always resoundingly clear just from being around him that he loved what he did.

After graduating from San Diego State in 1984, Fikes worked as a freelance writer and then spent three years as a staff writer for the Chula Vista Star-News. In 1990, he joined the staff of the San Diego Business Journal, where he worked for six years. Then he spent another year covering business for the San Diego Daily Transcript.

Because of the deep connections he had built in the local business community, Fikes took a brief career detour into corporate communications for a high-tech firm in 1997. He quickly realized his mistake. Despite the higher salary, Fikes missed working as a newspaper journalist. In 1997, he contacted then-North County Times business editor Pam Kragen looking for a staff-writing job. He was hired immediately.

Brad had a bit of the nutty professor about him when it came to style, but his brain worked like a computer, Kragen said.

He was able to store vast amounts of information and call on it to write knowledgeably, accurately, quickly and prolifically. After returning to the newspaper business, I remember Brad telling me that all he ever really wanted to do was to be a journalist because he loved the process of discovering something new and then sharing it with readers. He was very proud to work at the Union-Tribune.

He loved the job and the newsroom was his home.

Union-Tribune Publisher and Editor Jeff Light said, Bradley had a rare combination of intellect, curiosity and character. It made him a wonderful journalist.

By character, I mean the strength to be true to himself. But he also had a vulnerability that made you feel protective of him. He was a beloved figure. Our newsroom will miss him terribly.

Fikes is survived by three sisters, Sue Tate of San Diego; Vanessa Dimalanta of San Diego, and Kimberley Cross of San Diego.

Originally posted here:
Union-Tribune biotech writer Bradley J. Fikes, beloved by colleagues, dies at 61 - The San Diego Union-Tribune

Eileen Booker sat in her Southern California home last Sunday night, watching the Packers game like she does every week.

She grew up in Green Bay, and her sister still lives there. Her parents bought season tickets in 1957 and her father never missed a home game. She remembers sticking to frigid metal bleachers as a kid until the clock showed zeroes in the fourth quarter, win or lose, and always burning her lips with hot chocolate.

Still a die-hard fan today, Eileen was glued to her television for a prime-time game between the Packers and 49ers, even as her favorite team trailed, 10-0, early in the second quarter.

She had no idea her name was about to be plastered on TV screens across America.

After Packers outside linebacker ZaDarius Smith sacked 49ers quarterback Jimmy Garoppolo deep in 49ers territory, he immediately found the nearest camera and lifted his jersey, revealing a white undershirt that read, WE ...

Originally posted here:
How the Packers' Za'Darius Smith brought joy and awareness to one woman's cancer fight - The Athletic

Stem Cell Banking Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Stem Cell Banking industry overview and then goes into each and every detail.

Stem Cell Banking Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Stem Cell Banking also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

High potential of cord blood and tissues for the treatment of patients with autoimmune diseases is expected to propel the market growth. Moreover, currently available immunosuppressive agents such as steroids, induce long term side effects despite temporary improvements. According to the Health Research Funding, 2015, around 28% of cord blood transplants have been used to treat genetic diseases, with the most common genetic disease treated being severe combined immune deficiency, followed by aplastic anemia. According to the National Cord Blood Program, 2015, cord blood from unrelated donors has been used as an alternative to bone marrow or mobilized stem cells, as a source of hematopoietic stem cells, with over 35,000 stem cell transplants successfully performed worldwide.

Stem Cell Banking Market competition by top manufacturers/players, with Stem Cell Banking sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/1354

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1354

Stem Cell Banking Market Dynamics in the world mainly, the worldwide 2018-2026 Stem Cell Banking Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Stem Cell Banking market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Stem Cell Banking industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/1354

In this study, the years considered to estimate the market size of 2018-2026 Stem Cell Banking Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

The rest is here:
Stem Cell Banking Market to Expand Steadily in the Coming Years till 2018-2026 - Crypto Journal

The latest research report on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Ricerca Alfa, presents a detailed analysis concerning market share, market valuations, revenue estimation, SWOT analysis, and regional spectrum of the business. The report further highlights key challenges and growth prospects of the market, while examining the business outlook comprising expansion strategies implemented by market leaders.

The Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Request for Sample of this [emailprotected] https://www.ricercaalfa.com/page/request-sample/50850/Global-Circulating-Tumor-Cells-CTCs-and-Cancer-Stem-Cells-CSCs-Market

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Creatv MicroTech, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, Aviva Biosciences Corporation, ScreenCell, Silicon Biosystems includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc.

Methodology used in this report:

Our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. The research process begins with extensive data mining, using authentic sources such as trade magazines, technical publications, independent studies along with paid avenues such as ICIS, Hoovers, etc. Primary objectives of data mining include:

All the above factors are identified and analyzed in detail, with their present and expected market impact, which is quantified and used to derive market growth expectation. Market forecast is built using statistical analysis with models built around time-variance, regression and correlation analytics.

Market segment by Type, the product can be split into

CellSearch, Other, Type III,

Market segment by Application, split into

Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatment,

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request for this Report: https://www.ricercaalfa.com/publishersDetails/50850/global-1245-tetramethylbenzene-durene-market-research-report-2019-by-m.html

Questions that the report answers with regards to the competitive hierarchy of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market:

An overview of the regional spectrum:

Table of Content

1 Introduction Of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Deployment Model5.1 Overview

6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Solution6.1 Overview

7 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Vertical7.1 Overview

8 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Enquiry Before Buying: https://www.ricercaalfa.com/page/enquire/50850/Global-Circulating-Tumor-Cells-CTCs-and-Cancer-Stem-Cells-CSCs-Market

About Us:

Ricerca Alfa is one of the top market research, consulting, and report resellers in the business world, dedicated to assist worldwide organizations to deliver practical and lasting results through valuable recommendations about emerging technology and industry trends, granular quantitative as well as qualitative information. We have comprehensive database of market research reports that are backed by the prominent research analysts seeking reliable facts and unbiased market insights.

Contact Us:

https://www.ricercaalfa.com/

Ricerca Alfa

Galaxy One, Besides EON IT Park, EON Free Zone, Kharadi, Pune, Maharashtra, India 411014

+91 90213 50030 (India)

+1 619-663-3211 (U.S)

[emailprotected]

Continued here:
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Advanced Technologies & Growth Opportunities in Global Industry By 2025 -...

A new professional intelligence report published by Stats and Reports with titleGlobal Cancer Stem Cell Market Report 2025has the ability to help the decision makers in the most important market in the world that has played a significant important role in making a progressive impact on the global economy. The Global Cancer Stem Cell Market Report presents and showcases a vigorous vision of the global scenario in terms of market size, market potentials and competitive environment. The study is derived from primary and secondary statistical data and consists of qualitative and quantitative analysis of industry and key players. For the purpose of this study, the report includes major players such asThermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics, Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., OncoMed Pharmaceuticals, Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME, Inc..

Sample Report & Graphs & Charts @:https://www.statsandreports.com/request-sample/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Industry Overview of Global Cancer Stem Cell:To engage or target the Global Cancer Stem Cell Market, this study will provide a comprehensive view. It is important to keep Market knowledge up to date with Applications Stem Cell Based Cancer Therapy, Targeted CSCs, Product types Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others. If you have other players / manufacturers in your geography, or if you need regional or country-specific report, we can provide customizations based on your requirements.

This research will help you understand the markets or regions or countries that you need to focus on for years to channel efforts and investments to maximize growth and profitability. The report presents an in-depth analysis of key vendors or key players in the Market competitive landscape and Market.

Check Discount @https://www.statsandreports.com/request-sample/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

** We will also include opportunities to utilize in micro Markets that stakeholders can invest in, detailed analysis of key competitors and key services.

Furthermore, the years considered for the study are as follows:Historical year 2014-2018Base year 2019Forecast period** 2019 to 2025[** unless otherwise stated]

Sub-section of the Market are Listed below:

Product Types of Cancer Stem Cell Market:Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others.

Key Applications/end-users of Global Cancer Stem Cell Market:Stem Cell Based Cancer Therapy, Targeted CSCs.

Major Companies in the Market are:Thermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics, Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics, Inc., OncoMed Pharmaceuticals, Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME, Inc..

Global Cancer Stem Cell Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Key features and key features of the report are as follows.

Cancer Stem Cell Market overview Changing Market dynamics of industry In-depth Market segmentation by type and application Historical, current and planned Market size in terms of quantity and value Recent industry trends and developments Cancer Stem Cell Competitive landscape of the Market Major player and product delivery strategy Potential growth potential and niche Market / region Cancer Stem Cell neutral view on Market performance Market holders must have the information to maintain and strengthen their Market share.

Read Full TOC of Research Study at @https://www.statsandreports.com/report/294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Key Highlights of TOC:

Chapter 1: Global Cancer Stem Cell Market Industry Overview1.1 Cancer Stem Cell Industry1.1.1 Overview Major Enterprise Products1.2 Cancer Stem Cell Market Segment1.2.1 Corporate chain1.2.2 Consumer Distribution1.3 Pricing and Cost Overview

Chapter Two: Global Cancer Stem Cell Market Demand2.1 Segment Overview2.1.1 APPLICATION 12.1.2 APPLICATION 22.1.3 Other2.2 Global Cancer Stem Cell Market Size by Demand2.3 Global Cancer Stem Cell Market Forecast by Demand

Chapter Three: Global Cancer Stem Cell Market by Type3.1 By Type3.1.1 TYPE 13.1.2 TYPE 23.2 Cancer Stem Cell Market Size by Type3.3 Cancer Stem Cell Market Forecast by Type

Chapter Four: Major Region of Cancer Stem Cell Market4.1 Global Cancer Stem Cell Sales4.2 Global Cancer Stem Cell Revenue & Market share

..

Buy this Report:https://www.statsandreports.com/placeorder?report=294521-global-cancer-stem-cell-market-size-status-and-forecast-2019-2025

Key questions answered Who are the main competitors in the market and what are the key business plans? What are the key concerns of the five forces analysis of the Global Cancer Stem Cell Market? What are different prospects and threats faced by the dealers in the Global Cancer Stem Cell Market? What are the strengths and weaknesses of the key vendors?

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact:Stats and ReportsSatish K. (Global Sales Manager)Mangalam Chamber, Office No 16, Paud RoadSankalp Society, Kothrud, Pune, Maharashtra 411038Phone: +1 650-646-3808Email:sales@statsandreports.comWeb:https://www.statsandreports.comFollow Us on:LinkedIN|Twitter|

See the article here:
Cancer Stem Cell Market Analysis Focusing on Top Key Players Thermo Fisher Scientific, Inc., AbbVie, Inc., Merck KGaA, Bionomics, Lonza, Stemline...

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

GREENVILLE, S.C.Hailie and Treylin Hyman saw the bruising on their baby girls leg as a sign that the active 1-year-old was learning to walk.

But as a blood test would later reveal, little Maci was actually suffering from an extremely rare blood cancer that threatened her life without a risky treatment - atreatmentalmost as dangerous as the disease.

In the beginning, it was very scary, Hailie Hyman told The Greenville News.

I couldnt think of anything but the bad things, she confessed. It was all about the statistics. And the statistics arent good.

Terrifying months followed the diagnosis, punctuated by one critical complication after another, leaving the Boiling Springs couple to wonder if Maci would survive.

Somehow, though, the blue-eyed toddler pulled through.And now her family is looking forward to a special Thanksgiving with much to be grateful for.

Alyssa Carson is 18 and has a pilot's license: She wants to be in the crew that colonizes Mars

The Hymans journey began last February atMacis 1-year-old well-child checkup.

We had no idea anything was wrong, her mom said.But they did a routine (blood test) and a couple of hours later, we got a call saying her platelets were very low.

The Hymans were referred to a hematologist who found other abnormalities in Macis blood and scheduled a bone marrow biopsy to investigate further.

Hailie Hyman holds her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

During the procedure, the child suffered an aneurysm in an artery and went into cardiac arrest. The team performed CPR on her for 20 minutes before she was stabilized, her mom said.

Later, in the pediatric intensive care unit, she suffered internal bleeding, too.

It was really hard, she said. There were many nights that I would just pray and pray and pray.

Initially believing Maci had leukemia, doctors subsequently determined she had myelodysplastic syndrome, or MDS.

The condition occurs when abnormal cells in the bone marrow leave the patient unable to make enough blood, according to the American Cancer Society.

Its rare, afflicting as few 10,000 Americans a year, though the actual number is unknown.

Maci Hyman, 1, interacts with hospital staff before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

In children, its rarer still. Most people arediagnosed in their 70s.

We were told that just four out of 1 million children get it every year, Hailie Hyman said.

That made the diagnosis elusive at first, said Dr. Nichole Bryant, a pediatric hematologist-oncologist with Prisma Health-Upstate, formerly Greenville Health System.

Shes the only one Ive seen in my career, she said.

Maci had to have regular blood transfusions, antibiotics and other medications to fight the MDS, Bryant said. But the only hope for a cure was a stem cell transplant at the Medical University of South Carolina in Charleston.

When they said that was the only treatment plan for MDS, I of course went to Google, Hailie Hyman said. I read about transplant patients and ...all the complications. It was terrifying. But no matter how many bad things I saw, we had to do it. There is no other option.

The transplantis extremely risky.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

First, high doses of chemotherapy are given to destroy the diseased bone marrow, leaving the patient without an immune system, so fighting infections becomes a challenge. Then healthy donor marrow is infused.

Its also fraught with potentially life-threatening complications, including graft vs. host disease, which occurs when immune cells from the donor attack the patients body, Bryant said. Other complications include permanent kidney damage and gastrointestinal problems.

They have to go to hell and back, she said. But its the only option for long-term survival.

Maci had a really rough start, suffering lots and lots and lots of complications, Bryant said.

Her kidneys failed, so she wound up on dialysis. When she couldnt breathe on her own, she was put on a ventilator. And because she couldnt eat, she had to be tube fed.

Hailie Hyman looks at a fish tank with her daughter Maci, 1, before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

She had blistering sores in her mouth and throughout her GI tract, her mom said. Because her liver wasnt functioning properly, her abdomen filled up with fluid that had to be drained. She was bleeding so profusely in her lungs that one of them collapsed.

Maci, who was sedated through much of it, was put on full life support, she said.

That night we almost lost her, her mom said. We were in the hallway crying our eyes out. We didnt know what do to or think. It was pretty scary for a while.

Somehow, Maci made it.

There were so many times during her first months that it seemed like she would not survive, Bryant said. So the fact that she is here ... is really a miracle.

Macis family found an unrelated donor through the National Marrow Donor Program, enlisting hundreds of other people to join the registry in the process, Bryant said.

Nichole Bryant, M.D.(Photo: Provided)

It was an important part of their journey that maybe didnt directly benefit Maci, she said. But if everybody did that, we wouldnt have difficulty finding a donor for anybody.

Doctors have no explanation for why Maci got MDS. She didnt carry the genetic mutation for it and there is no family history.

She is a rare child - and not in a good way, her mom said, adding,Youve got to laugh sometimes or youre going to cry.

A dying man wanted one last beer with his sons: The moment resonated with thousands

Maci was admitted to MUSC on June 2 and released on Oct. 14.

The Hymans, both 22, spent the entire time in Charlestonwhile Hailies mom cared for their older daughter, Athena, now 2.

Treylins employer held his welding job open for him. And other friends and family members did what they could to help.

We had many, many people very generously donate to us to cover expenses at home and living expenses where we were, Hailie Hyman said.

We are thankful for everyone who helped us through it the cards, the gifts, the donations. Every single cent is greatly appreciated.

Maci's doing well, but recovery from a transplant can take months to years, Bryant said.

Her kidneys are functioning again so she was able to come off dialysis. But she still must take many medications, including anti-rejection drugs that suppress her immune system and leaveher at risk for infection. And she still must be tube fed.

She is miles ahead of where she was two months ago, Bryant said. But she still has a long way to go. Its a long, long road.

Macis mom says she can be up and playing one day and flopped over on the couch another. She still experiences a lot of nausea and vomiting, but is doing well compared to where she was.

Hailie Hyman pulls her daughter Maci, 1, in a wagon in the hallway before an appointment at the Prisma Health Pediatric Hematology Oncology Center Monday, Nov. 4, 2019.(Photo: JOSH MORGAN/Staff)

So as the nation pauses to give thanks this Thanksgiving, she says the family will be countingtheir many blessings family andfriends, Gods mercy, andthe doctors and nurses who saved Macis life.

She has battled a lot and overcome a lot, she said. I have no doubt she will be able to get through.

Want to know more about becoming a marrow donor? Go to bethematch.org.

Follow Liv Osby on Twitter:@livgnews

104-year-old woman bags first buck: 'Never underestimate the power of our senior citizens'

Indiana hospital sued: More than 1,000 patients potentially exposed to HIV or hepatitis

Read or Share this story: https://www.usatoday.com/story/news/health/2019/11/28/south-carolina-toddler-survives-rare-blood-cancer-risky-procedure/4321002002/

Read the original:
South Carolina toddler survives rare cancer and the risky procedure used to treat it - USA TODAY

Lynne D. Neumayr, MD; Carolyn C. Hoppe, MD, MPH; Clark Brown, MD, PhD

2 decades; in 2017, L-glutamine oral powder was approved for the prevention of the acute complications of SCD. During the last several years there has been a dramatic increase in research into treatments that address distinct elements of SCD pathophysiology and even new curative approaches that provide new hope to patients and physicians for a clinically consequential disease that has long been neglected.

Am J Manag Care. 2019;25:-S0

For author information and disclosures, see end of text.

Background

Sickle cell disease (SCD) is a common, severe disorder that includes congenital hemolytic anemias caused by inherited point mutations in the -globin gene.1 These mutations result in abnormal hemoglobin polymerization, which leads to a cascade of physiologic consequences, including erythrocyte rigidity, vaso-occlusion, chronic anemia, hemolysis, and vasculopathy.1 This change in the behavior of hemoglobin has profound clinical consequences, including recurrent pain episodes (known as sickle cellrelated pain crises or vaso-occlusive crises), hemolytic anemia, multiorgan dysfunction, and premature death.1 Newborn screening, early immunization, and prophylactic penicillin treatment in infants and children, as well as comprehensive management for pain and disease complications, have improved outcomes in these patients; however, the average life expectancy of a patient with SCD remains only about 40 to 50 years.2,3

Globally, it is expected that approximately 306,000 people are born every year with SCD; an estimated 79% of these births occur in sub-Saharan Africa. In the United States, approximately 100,000 people are living with SCD, including approximately 1 in 365 African Americans and 1 in 16,300 Hispanic Americans.4,5

The impact of SCD on patient quality of life (QOL) has been estimated to be greater than that of cystic fibrosis and similar to that of patients undergoing hemodialysis, which is widely recognized as having a severe impact on QOL.6 Impairments are seen across functional and QOL domains and are particularly profound in terms of pain, fatigue, and physical function.7,8

Management of SCD can be intensive, time-consuming, and costly, particularly in patients with recurrent acute pain episodes. On average, patients with SCD experience approximately 3 vaso-occlusive crises each year, of which at least 1 requires inpatient treatment and 1 requires emergency department management without admission.9 Among patients who require admission, the median length of stay is approximately 6 days.9 More than 90% of acute hospital admissions for patients with SCD are due to severe and unpredictable pain crises, and these crises are responsible for 85% of all acute medical care for these patients.10 Estimates of the lifetime care costs for SCD vary dramatically based on underlying assumptions, from approximately $500,000 to nearly $9 million.11,12

Few options are currently available for the management of SCD. Hydroxyurea, which until recently was the only FDA-approved drug for adults with severe SCD genotypes (and is also used off-label for adults with less severe genotypes and children ages 9 months to 2 years), improves the course of SCD and results in substantial cost savings.13,14 Unfortunately, hydroxyurea is underutilized and treatment adherence is poor for a variety of reasons.15 Recently, L-glutamine became the second drug approved for SCD in the United States.16

Red blood cell (RBC) transfusion is common in patients with SCD for the management of acute complications, and regular or chronic transfusion regimens are used for stroke prevention in at-risk patients. Despite being effective for the management of both acute and chronic complications of SCD,1 transfusion is associated with annual costs exceeding $60,000; it requires routine, costly iron chelation therapy to prevent liver and other organ damage as a result of iron overload; and it is associated with the risk of alloimmunization.12,17 Stem cell transplantation, while potentially curative, is limited by a scarcity of matched donors and the risks for adverse events (AEs) and death.18 Currently under investigation are novel gene therapies that offer considerable hope for a more broadly applicable curative therapy.

This review will first examine our current understanding of the pathogenesis of SCD and explore the broad range of clinical manifestations of this disease. It will then focus on the relatively limited current therapeutic options, recent clinical trials, and near-term therapies for the chronic and acute management of the disease.

The Pathogenesis of SCD

SCD is not a single disorder. Rather, it is a clinical entity that includes a number of heritable hemolytic anemias with widely variable clinical severity and life expectancy. All involve point mutations in the -globin gene, resulting in an abnormal hemoglobin referred to as hemoglobin S (HbS).19 In the most common forms of SCD, which are also the most severe, the patient inherits the sickling gene from both parents and produces HbS exclusively.19 The compound heterozygous forms of SCD are defined by the production of HbS and another abnormal -globin protein.19

The point mutation in the -globin gene results in the substitution of glutamic acid in position 6 with valine in the resulting protein.1 This small change in the amino acid sequence of hemoglobin has profound structural and functional consequences, because under low oxygen conditions, it produces a hydrophobic region in deoxygenated HbS that promotes binding between the 1 and 2 chains of 2 hemoglobin molecules, ultimately resulting in HbS polymerization into rod-shaped structures.

The polymerization of HbS changes both the shape and physical properties of RBCs, resulting in red cell dehydration, increased rigidity, and a variety of deleterious structural abnormalities, including the characteristic sickled RBCs from which the disease gets its name.20 The rigidity of deoxygenated RBCs contributes to vaso-occlusion by impeding their passage through the microcirculation.1 Repeated cycles of tissue hypoxia and reperfusion damage elicits upregulation of adhesion molecules, such as P-selectin and E-selectin, on the vascular endothelium. This promotes adherence of RBCs, white blood cells (WBCs), and platelets, further contributing to a propensity for vaso-occlusive events and a chronic inflammatory state.1,20,21

Hemolytic anemia is an important driver of the pathophysiology of SCD. The average RBC in homozygous SCD survives only approximately 10 to 20 days, compared with 120 days for normal RBCs.22 Destruction and release of the contents of RBCs into the circulation results in progressive endothelial dysfunction and proliferation, which may in part be due to scavenging of nitric oxide (a key regulator of vascular tone) by extracellular hemoglobin.20,23-25 The end result is an impaired vasodilatory response, chronic activation of endothelial cells and platelets, and an ongoing inflammatory state. Exposure of phosphatidylserine, which is normally only found on the inner surface of the RBC membrane, also occurs, and this predisposes cells to premature lysis and promotes the activation of coagulation pathways.26,27 Excess levels of adenosine, often related to stress, are also seen in SCD. Adenosine signaling contributes to the pathophysiology of SCD by stimulating the production of erythrocyte 2,3-bisphosphoglycerate, an intracellular signal that decreases oxygen binding to hemoglobin.28

Clinical Consequences of SCD

SCD is associated with a broad range of acute and chronic complications that have a profound impact on patients, their families, and society. As noted previously, patients with SCD can present with a broad range of manifestations and disease severities depending upon the underlying genetics of their disease; the discussion below primarily refers to the most common homozygous form of the disease.

Acute pain events affect approximately 60% of patients with SCD in any given year.29-31 Such events can begin as early as 6 months of age and may recur throughout the patients life. Acute pain events are responsible for more than three-quarters of hospitalizations in patients with SCD,32 and from the perspective of the patient, they are often considered the most important and disabling consequence of the disease.32,33 Many such events can be managed at home with oral analgesics, hydration, and rest; however, in some cases, patients must be administered opioids in the emergency department or hospital setting to achieve adequate pain control.34 Acute pain events are major contributors to the high healthcare utilization of many patients with SCD.32

Stroke is the most common, and most concerning, long-term risk of homozygous SCD. The risk for stroke in children with SCD is approximately 300 times higher than for children without SCD, and approximately 25% of adults with SCA will have a stroke.20,35 Silent cerebral infarcts occur in 27% of patients by age 6 years and in 37% by age 14 years; the prevalence of silent cerebral infarct in adults is less well defined, although it is likely that progressive injury occurs as patients age.36 Cognitive impairment is seen in 5 to 9 times as many patients with SCD as compared with patients without SCD, likely due to silent repetitive ischemic brain injury.29 The use of transcranial Doppler or MRI to screen patients can help to identify patients who would benefit from additional measures to decrease the frequency and severity of stroke.20

Continued here:
Sickle Cell Disease: Current Treatment and Emerging Therapies - AJMC.com Managed Markets Network

What if someone told you that theres a disease you could catch where you couldnt feel any symptoms coming on? And that this occurs every 1.2 seconds somewhere in the world?

What if you were stricken with this disease then there would be a 5% chance youd lose a limb within a year and a 50-70% chance youd be dead in five years? What if you were told that this problem cost more than the five most expensive cancers in the U.S. but far less than one one-thousandth of comparative federal and private funding is spent on attacking it?

Ladies and gentlemen, please allow me to introduce you to the humble diabetic foot ulcer. While the problem may strike at the end of the body, far away from the heart or the brain, its effects are far-reaching.

I have spent my career treating and researching the lower extremity complications of diabetes. Based on my research and experience, I believe our society could eliminate immeasurable suffering if we collectively paid more attention to this problem.

OK, I know this isnt a sexy topic. Foot wounds are ugly. Many people who have them are poor. But bear with me. They are a reality for far too many Americans and people across the globe. The ages of these patients are bimodal, in that there is one population of people who are old and getting older. Conversely, with more and more people being diagnosed with Type 2 diabetes earlier, there is a population that is younger than ever being afflicted with wounds, infections and amputation. Ignoring the problem is an example of ignoring the needs of a silent and vulnerable population.

About 31 million people in the U.S. have diabetes, and about half a billion worldwide.

Diabetic foot ulcers develop because people with diabetes slowly lose the gift of pain. Over many years, people with diabetes lose feeling in their extremities. This occurs first and generally most profoundly in their feet.

Once this occurs, people with diabetes might wear a hole in their foot, just as you or I might wear a hole in a sock or shoe. This hole is called a diabetic foot ulcer.

About half the time, the ulcer will become infected. This increases the risk of further tissue damage and, in the face of frequent vascular disease, high-level amputation. Often all of this occurs with few, if any, symptoms until it is too late.

There is also good news. Studies have suggested that high-level amputations seem to decrease when interdisciplinary care is in place, regardless of the country.

Interdisciplinary teams consist of podiatric and vascular surgeons, the so-called Toe and Flow model. The concept is simple; these two specialists, can manage a great deal of the medical, surgical and biomechanical aspects of healing and aftercare.

When we add core physical therapy to this, then the threesome (what we in the field call Toe, Flow and Go) is really quite formidable. For example, our clinics at the University of Southern California and Rancho Los Amigos in Los Angeles have active participation from more than eight specialists ranging from plastic surgery to prosthetics/orthotics, to occupational therapy to nutrition to general practice to infectious disease to diabetology to nurse case management.

Truly, it takes a village to preserve a limb.

It has long been said in wound care that its not what one puts on a wound that heals it, but what one takes off. That maxim is absolutely true in the diabetic foot. Protection of the wound is key.

The gold standard for protecting the wound has been, believe it or not, to put the patient into a special cast. This device works so well because it protects the foot in a process known as offloading, or taking the burden off the foot. By its design, this cast is not easy to remove.

While this has been my personal favorite device to heal these foot wounds, patients dont like it and most doctors dont, either. In fact, fewer than 2% of centers in the country use this as their primary means of offloading. Reasons for this include fear of putting an open wound into a cast (even though the data largely refute this), the time required to apply and remove it and patients being miserable in a hot and heavy device.

Very recently, tech company offshoots have begun to partner with prosthetic/orthotic companies to create next-gen devices that can coax patients into wearing their protective device rather than forcing it upon them. They are using phone calls and a smartwatch.

After focusing on offloading pressure, the next question is what can be done to heal the wound.

Technologies ranging from fancy vacuums, to donated placental tissue, to repurposing blood cells into a dressing to topical oxygen systems have shown recent promise. Active research is being conducted with stem cell sheets consisting of specialized cells seeded on a clear sheet, spread-on skin, and gene therapy.

As challenging as healing the wound heals, the real challenge is whats next. Following healing, 40% of foot wounds will recur in one year, about two-thirds at three years, and nearly three out of four at five years.

At USC, along with colleagues in the National Health Service in the U.K., we have developed remission clinics designed to extend and promote an active life for this high-risk patient population.

This has also been combined with things like smart insoles, socks and home-based bathmats that can identify wounds before they occur. These technologies will likely initially be subscription-based but may expand beyond that.

Diabetic foot ulcers are common, complex and costly. Theyre sinister in that they come on quietly. Perhaps, though, it is now up to us to alert our own families, communities and leaders to this condition. It is, I believe, only by teaming up that we can stem the tide and preserve not only limbs, but extend lifespan, healthspan and hope.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can read us daily by subscribing to our newsletter. ]

See the article here:
Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference - The Conversation US

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

To obtain all-inclusive information on forecast analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Request a PDF Brochure Here https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

Here is the original post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market to Observe Strong Development by 2023 - Montana Ledger

Global Blood Therapeutics, Inc. (GBT) confirmed that the FDA has approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease in adults and children 12 years of age and older. According to the company press release, Oxbryta is the "first and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy."

Earlier, the company presented updates on corporate developments on 10/8/2019 at its Analyst & Investor Day. Global Blood is a clinical-stage biopharmaceutical company having expertise in blood biology and structural and medicinal chemistry. The company's lead product candidate is voxelotor ('GBT440), an oral, once-daily therapy, designed to modulate hemoglobin affinity for oxygen for the treatment of sickle cell disease (SCD). SCD is an inherited blood disorder caused by a genetic mutation in the beta-chain of hemoglobin, leading to the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

HbS polymerizes forming rigid rods within a red blood cell (RBC). The inflexible polymer rods arranged in a sickle shape, cause hemolytic anemia (destruction of RBCs) that can result in multi-organ damage and even early death. This sickling process blocks capillaries and small blood vessels. Blocked bloodflow to organs results in inadequate oxygen delivery (hypoxia) to body tissues, which makes the SCD patients suffer recurrent and unpredictable episodes of severe pain, ultimately leading to physical and psychosocial disabilities. Voxelotor is designed to inhibit HbS polymerization.

Voxelotor had been granted priority review for the treatment of SCD, with PDUFA date set to February 26, 2020. Priority review shortens the FDA review time from the standard 10 Months to 6 months. The accelerated approval 3 months ahead of PDUFA speaks for the importance of this novel drug in the eyes of the FDA.

The NDA was based on data from the multi-national Phase 3 HOPE study, which demonstrated statistically significant and sustained improvements in hemoglobin with voxelotor. Looking at the critical need for new SCD treatments, the U.S. FDA earlier granted Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations to voxelotor for the treatment of patients with SCD. The European Medicines Agency (EMA) has also included voxelotor in its Priority Medicines (PRIME) program, while the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.

Design: The efficacy and safety of two dose levels of voxelotor, 1500 mg and 900 mg, administered orally once daily, was compared with placebo in persons with SCD in a multicenter, Phase 3, double-blind, randomized, placebo-controlled trial "HOPE." The percentage of participants who had a hemoglobin response, defined as an increase of more than 1.0 g per deciliter from baseline at week 24 in the intention-to-treat analysis was the primary endpoint. 274 participants in total were randomly assigned in a 1:1:1 ratio to receive a once-daily oral dose of 1500 mg of voxelotor, 900 mg of voxelotor, or placebo. Most participants had sickle cell anemia (homozygous hemoglobin S or hemoglobin S0-thalassemia), and approximately two thirds were receiving hydroxyurea at baseline.

Results: The Phase 3 study met the primary endpoint with nearly 60% of patients achieving >1 g/dL increase in Hb vs. placebo (p<0.001). A significantly higher percentage of participants had a Hb response in the 1500-mg voxelotor group (51%; 95% confidence interval [CI], 41 to 61) than in the placebo group (7%; 95% CI, 1 to 12), in the intention-to-treat analysis. Anemia worsened between baseline and week 24 in more placebo-treated participants than in each voxelotor dose group.

At week 24, the 1500-mg voxelotor group had significantly greater reductions from baseline in the indirect bilirubin level and percentage of reticulocytes than the placebo group. Adverse events (AEs) of grade 3 or above occurred in 26%, 23% and 26%, in the 1500-mg voxelotor group, the 900-mg voxelotor group, and the placebo group respectively. Most AEs were not treatment emergent either with the trial drug or placebo. Voxelotor increased hemoglobin levels and reduced markers of hemolysis significantly. The results are consistent with inhibition of HbS polymerization.

(Image source: Company presentation)

The company in agreement with the U.S. FDA, has already designed the post approval, confirmatory study of voxelotor, utilizing TCD flow velocity as the primary endpoint.

There are millions of SCD patients worldwide with 90,000 to 100,000 in the U.S. and about 60,000 in Europe. SCD is a congenital disease, with symptoms and organ damage starting in the early years of life. It is estimated that worldwide 250,000 to 300,000 children are born annually with SCD, which is concentrated in populations of African, Middle Eastern and South Asian descent. SCD treatment is costly, with average annual cost in the U.S. being more than $200,000 for an adult, which can lead to aggregate expense of more than $8 million over an assumed 50-year lifespan. Newborn screening, which is required by all states in the U.S., and development of new therapeutics is hence a critical need of the market.

GBT raised approximately $197.8 million in net proceeds from a public offering in June 2019 and related over-allotment option exercise in July 2019. GBT had cash, cash equivalents and marketable securities totaling to $731.7 million as of 6/30/2019. Looking at the cash burn of about $61 million in the most recent quarter ending 6/30/2019, GBT's fund position seems to be at an adequate level to carry through the commercialization of voxelotor, and other development activities without further dilution of the stock. Insiders sold a negligible, less than 15000 shares in the last 52 weeks. Institutional holding increased over 2% in 2Q-2019.

The company awarded more than $200,000 in grants to five nonprofit organizations as part of the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL). The grant funding will support projects to improve access to high-quality healthcare for SCD patients in the U.S. The company has launched two SCD awareness campaigns while also hiring all commercial leads as of 1H-2019.

Voxelotor does not have a direct competition as it is attacking the root cause of SCD with a new first-in-class therapy. It faces indirect competition from (1) Bristol-Myers Squibb's (BMY) hydroxyurea (DROXIA or Hydrea) and its generic form, which are approved for "reducing the frequency of painful crises and need for blood transfusions in patients with sickle cell anemia for the treatment of adults with SCD," and (2) Endari (L-glutamine oral powder), marketed by Emmaus (OTCQB: EMMA), approved for the reduction of acute complications in SCD patients of age five years and above. GBT will also face competition from one-time therapies for patients with severe SCD, like hematopoietic stem cell transplantation, gene therapy and gene editing.

bluebird bio, Inc. (BLUE) has a gene therapy candidate in clinical development - LentiGlobin BB305, which the company plans to pursue on an accelerated development path. Pfizers (PFE) rivipansel is in a Phase 3 trial however it failed the treatment goals. Novartis (NVS) crizanlizumab (SEG101), an anti-P-selectin monoclonal antibody for the prevention of vaso-occlusive crises (VOCs) in patients with SCD is in clinical development with a breakthrough designation. The U.S. FDA has accepted for a priority review of crizanlizumab based on its Phase 2 SUSTAIN study results. Estimated PDUFA date is 1/15/2020. GBT also has an anti-P-selectin monoclonal antibody therapy inclacumab, in clinical development, under worldwide, exclusive but non-diagnostic license from Roche (OTCQX:RHHBY).

Various patents covering voxelotor, including its composition of matter, methods of use and a polymorph of voxelotor will expire between 2032 and 2035. Patents that may issue from GBTs pending patent applications relating to voxelotor in the United States or from corresponding foreign patent applications, if issued, are expected to expire between 2032 and 2037. Some patents related to voxelotor are held jointly with the Regents of the University of California.

GBTs other risk is competition. For a long time, Lentiglobin has been talked about as a major competition, and while it is aimed as a curative treatment, it is expensive, and still in a much earlier stage, with the Phase 2/3 trial in planning stage only. Crizanlizumab is also not a real competition either, because it is a downstream therapeutic approach compared to GBTs.

The stock price was near the midpoint of the 52-week high and low before the approval. The approval has pushed the price up by about 20% in the time since the original version of this article was written. However, I strongly believe there's considerably more upside to this stock as the drug gets to the market in the next couple of weeks and starts generating revenue.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
Global Blood Therapeutics: Oxbryta Is Finally Approved - Seeking Alpha

Job Description

Junior Research Fellow (JRF)for Translational Research - Stem Cell-based Neural Tissue Engineering Project:

Title of the Project: Human dental pulp stem cells as a multifaceted tool for accelerating neural regenerationDuration: 3 YearsLocation: Vellore Institute of Technology, Vellore

Qualification:

M.Sc/ M. Tech (Biomaterials, Tissue Engineering, Biotechnology, Biology, and Biomedical Sciences) with a minimum of 55% marks.

Skill set required:

Candidate with work experience in biomaterial synthesis, scaffold fabrication and stem cell culture is desirable.

Stipend: Rs.20,000/- per month (consolidated)

Work functions of the JRF: The JRF will be required to do full time research related to this specific project, in particular biomaterial synthesis and characterization, scaffold fabrication, biological assays, dental stem cell culture.

Principal Investigator:

Dr.Murugan RamalingamCentre for Biomaterials, Cellular and Molecular Theranostics (CBCMT)School of Mechanical EngineeringVellore Institute of Technology (VIT),Vellore 632014

Send your resume along with relevant documents pertaining to the details of qualifications, experience and latest passport size photo on or before (30/11/2019) through online http://careers.vit.ac.in.

No TA and DA will be paid for appearing for the interview.

Shortlisted candidates will be called for an interview at a later date which will be intimated by email.

Salary:Not Disclosed by RecruiterIndustry:Education / Teaching / TrainingFunctional Area:Teaching, Education, Training, CounsellingRole:Trainee

Keyskills

stem cellsbiotechnologybiologybiomaterials

Desired Candidate Profile

Please refer to the Job description above

Education-

UG:B.Tech/B.E. - Bio-Chemistry/Bio-Technology, Biomedical, B.Sc - BiologyPG:M.Tech - Bio-Chemistry/Bio-Technology, Biomedical, MS/M.Sc(Science) - Biotechnology, Biology

Company Profile

Vellore Institute of Technology

VIT was established with the aim of providing quality higher education on par with international standards. It persistently seeks and adopts innovative methods to improve the quality of higher education on a consistent basis.The campus has a cosmopolitan atmosphere with students from all corners of the globe. Experienced and learned teachers are strongly encouraged to nurture the students.

Link:
Junior Research Fellow for Stem Cell-Based Neural Tissue Engineering Project job with VELLORE INSTITUTE OF TECHNOLOGY | 187070 - Times Higher...

The tooth is a biological organ and consists of multiple tissues including the cementum, dentin, enamel, and pulp. Dental caries, Periodontal disease, and tooth fracture are the three main factor for tooth loss. Tooth Regeneration is the specialty concerned with the treatment of dental diseases such as a cavity, periodontal disease and fracture of the tooth. Dental caries is also known as tooth decay is the main oral health problems in most of the industrialized countries. Facial trauma also the major cause of tooth loss. Tooth loss leads to people mentally and physically disturb and it also affect the self-confidence and quality of life. Tooth regeneration is the process of individual tissue and the whole tooth development. Basically, it is the process of restoring the loss of natural teeth. Tooth regeneration is stem cell-based regenerative medical procedure which is used in stem cell biology sector and tissue engineering. There are two approaches used in the build of new whole teeth, in vivo implantation of tooth germ cells which were previously generated from stem cells and grow in vitro cells and another organotypic culture is an appropriate technique for the generation of teeth. The process of tooth regeneration imitates the natural tooth development using stem cells. In another way instead of whole teeth regeneration, Different part of the teeth regenerates such as Enamel regeneration, Dentin regeneration, Pulp regeneration, and periodontal regeneration.

Globally increasing incidence and prevalence of dental problems such as a cavity, periodontal disease, and tooth fracture are the major factors driving the growth of the Tooth Regenerations market. Innovative new techniques in Tooth regeneration such as cell homing, cell transplantation is expected to increase the acceptance of Tooth Regenerations. Tooth regeneration not only regrowth the entire tooth but also the restoration of individual components of the tooth such as dentin, cementum, enamel and dental pulp and these individual regeneration process is anticipate the boost the market growth of tooth regeneration market. Dental implantation also increases the growth of tooth regeneration market. People are very keen interested in the tooth regeneration and they are also giving more importance to the aesthetic aspects of dental products, which is expected to increase the Tooth Regenerations and dental market over the forecast period. The increasing demand for a customized Tooth Regeneration with the specifications and other dental decorative installations is the key factor anticipated to propel the demand for Tooth Regenerations worldwide.

The Global Tooth Regenerations market is segmented on the basis of application, Demographics, technique and by End user

Based on the Application type Tooth Regenerations market is segmented as:

Based on the Demographic Tooth Regenerations market is segmented as:

Based on the Technique, Tooth Regenerations market is segmented as:

Based on the end user Tooth Regenerations market is segmented as:

According to WHO, approx.30% the geriatric population is affected by the complete loss of teeth. Rapidly increasing Dental cavities and periodontal diseases are the major drivers in the Tooth Regenerations market. The global Tooth Regenerations market by application is expected to be dominated the market of Tooth Regenerations, out of which Enamel segment is expected to generate maximum revenue share over the forecast period. By end user, Tooth Regenerations market is expected to be dominated by dental clinics and hospitals. The manufacturers in the concerned market are focusing on manufacturing advanced products for better patient compliance and make the procedure easier. The market of tooth regeneration is anticipated to boost by stem cell regeneration technology.

The global Tooth Regenerations market is expected to be dominated by North America due to higher adoption and significant geriatrics population which also increase the demand for dental service for Dental caries and Periodontal disease. Europe is expected to be the second most lucrative Tooth Regenerations market due to rising funds for research for the growing patient population. Asia-Pacific is expected to be the fastest growing Tooth Regenerations market due to rapidly increasing incidence of dental surgery, general prosthetic fixation. Latin America and Middle East & Africa are expected to be the least lucrative market due to Low awareness regarding the use of Tooth Regenerations technology and comparatively less developed healthcare infrastructure in major regions.

Examples of some of the market participants in the global Tooth Regenerations market identified are DENTSPLY Implant, Unilever, Datum Dental, Institut Straumann AG, Keystone Dental, Inc., Zimmer Biomet, Wright Medical Group N.V., Integra LifeSciences, CryoLife, Inc, BioMimetic Therapeutics, Inc, Cook Group and among others.

Read more:
Tooth Regenerations Market: Global Industry Trend Analysis 2013 to 2017 and Forecast 2018 2026 - Statsflash

Stem Cell Banking Market 2019 Industry report provides detailed statistics and accurate market figures, viz. market share, CAGR, gross margin, and those related to revenue, production, consumption, and sales. It also provides a regional analysis of the global Stem Cell Banking market to unveil key opportunities available in different parts of the world. This all analyzed data will help a new player and existing players to take a critical decision.

Get Sample Copy of this Report @ https://www.orianresearch.com/request-sample/1369382

The key players profiled in the market include: Cord Blood Registry Systems, Cordlife, Cryo-Cell International, Cryo-Save AG, LifeCell International, StemCyte, ViaCord, Global Cord Blood, Smart Cells International and Vita34

The global Stem Cell Banking market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Growing awareness on the therapeutic potential of stem cells coupled with the increasing investments in stem cell-based research will aid in augmenting the market growth. However, high operational costs of stem cell banking and stringent regulations will impede the market growth during the analysis period.

The global stem cell banking market is segmented on the basis of source, application, service type and region. Based on source the market is segmented into Placental Stem Cells (PSCs), Human Embryo-derived Stem Cells (hESCs), Bone Marrow-derived Stem Cells (BMSCs), Adipose Tissue-derived Stem Cells (ADSCs), Dental Pulp-derived Stem Cells (DPSCs) and other stem cell sources. Based on application the market is segmented into personalized banking applications, clinical applications, hematopoietic disorders, autoimmune disorders, other diseases, research applications, disease treatment studies, life science research and drug discovery. Based on service type the market is segmented into sample collection & transportation, sample processing, sample analysis and sample preservation & storage. Based on region, it is studied across North America Europe, Asia-Pacific, South America and Middle East and Africa.

No of Pages: 121

Key Benefits of the Report:

* Global, regional, by type, storage capacity, and by end user wise market size and their forecast from 2015-2026

* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market

* Detailed analysis on product outlook with market specific Porters Five SSDs analysis, PESTLE analysis, and Value Chain, to better understand the market and build expansion strategies

* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key product, and unique selling points

* Analysis on key players strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market

* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, by type, storage capacity, and by end user with qualitative and quantitative on premise and facts

The encrypted hard drives market is primarily segmented based on type, by storage capacity, by end user, and region.

Order a copy of Global Stem Cell Banking Market Report @ https://www.orianresearch.com/discount/1369382

On the basis of source, the market is split into:

* Placental Stem Cells (PSCs)

* Human Embryo-derived Stem Cells (hESCs)

* Bone Marrow-derived Stem Cells (BMSCs)

* Adipose Tissue-derived Stem Cells (ADSCs)

* Dental Pulp-derived Stem Cells (DPSCs)

* Other Stem Cell Sources

Based on end user, the market is divided into:

* Personalized Banking Applications

* Clinical Applications

* Hematopoietic Disorders

* Autoimmune Disorders

* Other Diseases

* Research Applications

* Disease Treatment Studies

* Life Science Research

* Drug Discovery

On the basis of service type, the market is split into:

* Sample Collection & Transportation

* Sample Processing

* Sample Analysis

* Sample Preservation & Storage

These enterprises are focusing on growth strategies, such as, technological advancements, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Target Audience:

* Stem Cell Banking Manufacturers

* Industry Participants and Associations

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, research and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and product trends and dynamics, and product capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their Market impacts using the weighted average analysis to derive the Market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

* Manufacturers

* Suppliers

* Distributors

* Government Body & Associations

* Research Institutes

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email: [emailprotected]

Website: http://www.orianresearch.com/

Go here to see the original:
Stem Cell Banking Market Size, by Source (Placental Stem Cells), by Application (Personalized Banking Applications), by Service Type (Sample...

LONDON--(BUSINESS WIRE)--The global cell separation market is poised to grow by USD 7.12 billion during 2020-2024, progressing at a CAGR of over 17% during the forecast period. Request Free Sample Pages

Read the 142-page research report with TOC on "Cell Separation Market Analysis Report by End-User (Academic institutions and research laboratories; Pharmaceutical and biotechnology companies; and Hospitals and clinical testing laboratories), by Geography (North America, Europe, Asia, and ROW), and Segment Forecasts, 2020 - 2024"

The market is driven by the increasing use of cell separation in cancer research. In addition, the rising focus on personalized medicine is anticipated to further boost the growth of the cell separation market.

The increasing use of cell separation in cancer research will be one of the major drivers in the global market. Over the last few years, cell separation has been used along with imaging, proteomics, and molecular biological methods to identify and characterize cancer stem cells. This helps in the early diagnosis of tumors, monitoring of circulating tumor cells, and evaluation of intratumor heterogeneity. Also, the incidence of cancer is increasing rapidly, especially amongst women. Cervical and breast cancers are the most common types in the world. The rising incidence of cancer is encouraging further research in the field. Moreover, advances in computer techniques, optics, and lasers introduced a new generation of cell separation techniques which are capable of high speed processing of single cell suspensions. These factors will boost the global cell separation market growth during the forecast period of 2020-2024.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Cell Separation Market Companies:

Akadeum Life Sciences

Akadeum Life Sciences owns and operates the businesses under various segments such as T cell isolation kits, B cell isolation kits, red blood cell products, Streptavidin products, and CD45 products. The product offered by the company is human T Cell isolation kit. This product uses streptavidin-conjugated BACS microbubbles and biotinylated antibodies for cell separation.

Becton, Dickinson and Co.

Becton operates the business under three segments, which include BD medical, BD life sciences, and BD interventional. The companys key offering include the BD IMag cell separation magnet. This product is used to attract labeled cells to the adjacent walls of tubes, allowing the removal of the supernatant, which contains unlabeled cells.

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. has business operations under various segments, namely life science and clinical diagnostics. The product offered by the company is the ddSEQ single-cell isolator. This product is offered as an automated device to process hundreds to tens of thousands of cells per day.

Cell Microsystems, Inc.

Cell Microsystems, Inc. operates the business under three segments, which include CellRaft AIR System, CytoSort Array, and CellRaft System for inverted microscopes. The companys key offerings include the CellRaft AIR System. This product is available with an automated precision X-Y stage and a microscope with three-channel fluorescence imaging capabilities. It is designed to reduce the time taken for cell separation.

Danaher Corp.

Danaher Corp. operates the business through the following segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The companys key offering in the cell separation market include Avanti J-26S XP. This product is offered as a centrifuge, which includes the elutriation particle separation functionality.

Register for a free trial today and gain instant access to 10,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cell Separation End-User Outlook (Revenue, USD Million, 2020 - 2024)

Cell Separation Regional Outlook (Revenue, USD Million, 2020 - 2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on HealthCare are:

Cell Isolation Market Global Cell Isolation Market by product (consumables and instruments), end-users (AR, PB, CRO, and others), and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Read the original:
Global Cell Separation Market 2020-2024 | Evolving Opportunities with Akadeum Life Sciences and Becton, Dickinson and Co. | Technavio - Business Wire

Stem Cell Banking Market Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 20192026Overview: Stem cells are undifferentiated biological cells that can distinguish into specialized cells, tissue, or an organ. The process of storing these stem cells for the treatment of life-threatening diseases in the future is called stem cell banking. Nearly 500 stem cell banks are functioning globally, and every bank is now striving harder to increase their market share. Stem cell banking has applications in cerebral palsy, thalassemia, leukemia, diabetes, autism, and others. Cerebral palsy holds the major share of nearly quarter of the market share among the various applications. Private stem cell banks are implementing innumerable publicizing strategies to upsurge their product visibility among people.

Key Players: Esperite, Caladrius Biosciences, Via Cord, CBR Systems, Smart Cells, Life Cell, China Cord Blood, Cryo-Cell, StemCyte, Cordvida, ViaCord, Cryoviva, and other predominate & niche players.

Get Sample copy of this Report: http://contrivedatuminsights.com/Home/RequestaSample/2433

The market is driven by factors such as easy method of extraction of stem cells from the samples, increasing birth rate, increased awareness of stem cell therapeutics, and increasing potentials of stem cell treatment. Alongside, the collaboration among the cord blood banks, increasing investments and fundings, and automation of procedures for the banking of stem cells are providing opportunities for the growth of the stem cell banking market. However, intense competition, high operating costs, changes in legal regulations, and high entry barriers are the major factors hampering the market growth.

Market Analysis: The Stem Cell Banking Market is estimated to witness a CAGR of 16.4% during the forecast period 20192026. The market is analyzed based on three segments, namely product types, end-users, and regions.Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the stem cell banking market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India, China, and Japan are set to be the most attractive destinations due to the large untapped market.

Product Types Analysis: The stem cell banking market by products is segmented into umbilical cord blood & cord tissue, and adult stem cell banking. The umbilical cord blood & tissue occupies the major share in the market and is also expected to grow at a fast CAGR during the forecast period. The dental stem cell banking and menstrual blood stem cell banking are the latest diversifications in the stem cell banking market. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the global stem cell banking market.

Get Special Pricing: http://contrivedatuminsights.com/Home/GetSpecialPricing/2433

Competitive Analysis: These days, stem cell banks exist in most of the developed and developing nations. Around 450 companies are publicizing cord blood banking services internationally, which signifies intense competition in the market. Globally, China Cord Blood Corporation (CCBC) is expected to be the fastest growing stem cell bank worldwide and in the US, it is Amricord. In 2014, the company Amricord achieved 2,200% growth rate from 2011-2013. Future Health Biobank, American Cryostem, Adicyte, Adisave, Celltex, and Vault Stem currently hold around two-thirds of the Mesenchymal Stem Cells (MSC) storage market. However, at present, these companies are still trivial but are swiftly intensifying. Cryostem witnessed its revenue to nearly double in 2016 from $400,000 to almost $800,000.

Benefits: The report provides complete details about the usage and adoption rate of stem cell banking in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives toward the stem cell therapy and banking adoption in the upcoming years along with the details of commercial devices available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyse before investing or expanding the business in this market.

For More Information: http://contrivedatuminsights.com/Home/InquiryBeforeBuying/2433

Table of Contents

Global Stem Cell Banking Market Research Report

Chapter 1 Global Stem Cell Banking Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export

Chapter 6 Production, Revenue (Value), Price Trend by Type

Chapter 7 Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Market Forecast

Any special requirements about this report, please let us know and we can provide custom report.

Read the rest here:
Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger

A new study by Rutgers University researchers suggests that two genes expressed in the intestinal cells that line the inside of the colon may also be involved in cancer development.

Recent studies have shown that intestinal stem cells can increase in animals on a high fat Western diet, potentially explaining an elevated cancer risk from such a diet.Diet being able to control cell proliferation is an interesting research development, particularly the convergence of dietary factors and dysregulated gene signaling driving malignant transformations and promoting an adenoma-to-adenocarcinoma progression.

This new study suggests a novel connection between HNF4A and HNF4G genes, diet and cancer.Genetic expression of HNF4 has previously been shown by to be heavily influenced by the gut microbiota, which in turn can influence a multitude of intestinal disorders.

Non-host gene regulation was further explored in this study by using a high fat diet to test how these genes work, and the researchers discovered they help co-regulate stem cell proliferation, as well as help intestine cells burn dietary fat. This was done by isolating cells from knockout and control mice and observing intestine stem cell proliferation under conditions of high fat and control. Mice that had both HNF4A and HNF4G knocked out were unable to have their stem cells proliferate under high fat conditions.

Intestinal stem cells undergo constant renewal and fuel the continuous turnover of the lining of the intestine. People naturally lose millions of intestinal cells daily, much like they lose skin cells. If this rate of replication is not closely controlled, it can quickly lead to malignancy. Lack of proliferation can be very problematic for the colon and damaging to lower layers of cells.

This [research] is important because scientists have shown that when theres too much dietary fat in the intestine, stem cell numbers increase, boosting susceptibility to colon cancer, said senior author Michael Verzi, an associate professor in the Department of Genetics in the School of Arts and Sciences at Rutgers UniversityNew Brunswick.

Rutgers scientists believe HNF4A and HNF4G help stem cells burn fat, providing them energy. By linking gene activation, cell replication number, diet and cancer risk, scientists might be able to better understand the cancer development process in high risk patients. Going forward, the researchers plan to continue studying whether these two genes alter stem cell numbers and cancer risk alongside a high fat diet, said Verzi.

Colorectal cancer (of the colon or rectum) is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, over 100,000 Americans will be diagnosed with colon cancer this year. This cancer is also the second most deadliest in the United States, but due to a combination of increased screening and heightened awareness the death rate has been dropping. However, in patients under the age of 55, the death rate of colon cancer has increased each year by 1% since 2007. Approximately 50,000 colon cancer patients are expected to die in 2019.

Read this article:
New Link Discovered Between Cells That Burn Fat and Colon Cancer - Clinical OMICs News

Imagine going from being an active individual to not being able to move any part of your body at all.

For Chris Barr, that was his reality when life came to a sudden halt for him two years ago.

Its exactly like it is in the movies where, you know, its like a fish-eye lens opening up. And the doctor says -- Youre paralyzed from the neck down. And you had a really bad neck injury, Chris told Good Morning America.

It was a day like any other for Chris who was out surfing, but things took a turn when he woke up in a hospital bed not remembering what happened last.

The prognosis was -- was bad, said Chris. And bad meaning, you know, probably a 95% to 97% chance that Ill have nothing below my neck.

After the doctor delivered the devastating news that his surfing accident left him with spinal cord injuries, Chris felt hopeless about the life ahead without motion and freedom -- ultimately wanting to end his life and even asked his wife, Debbie, for permission to pull the plug.

But Debbie convinced her husband not to give up so easily and asked him to give it a little more time despite the odds -- and he agreed.

One day at a time, Debbie was there every step of the way in rehab and physical therapy sessions to make small improvements. Things were looking up when he was able to move a toe, his leg and even his hands, but then the progress plateaued.

You ask yourself, Is that all there is? Is this all the further Im gonna go? Is this -- is this it? said Chris.

It wasnt until the Barrs received a phone call from Dr. Mohamad Bydon when things began looking up again.

Bydon, a spinal cord researcher, was leading an innovative trial at the time at the Mayo Clinic in Rochester, Minnesota. On the phone, he told Chris about his potentially historic trial that would include him as part of a 10 patient study.

Bydon explained that the trial would take stem cells from Chriss own stomach fat and would be injected into his spinal cord to regenerate and repair the injury -- something unheard of and never done with stem cells before.

Despite the uncertainties that came with being patient number one for the procedure, Chris was game.

You -- you gotta understand its -- you know, youve got absolutely nothing to lose, said Chris. I mean, this is exactly why I stuck around was to do something. Listen -- you know, I feel blessed to have the opportunity to participate in this. You know, whatever happened I was, Yeah, lets do this.

In just a short amount of time after the procedure, Chris said he saw improvements quickly when he first started getting feeling back in his legs -- something he hadnt experienced for almost a year.

After we treated him, the improvements started to come quickly, said Byron. And small things, being able to tie his shoes, you know, things that werent happening.

But, as was the hope with the procedure, Chris surprised everyone -- and even himself -- when he started walking.

Now, Chris milestone has proving that Bydons procedure is a potentially groundbreaking one for spinal cord injuries.

This is a first step in developing a breakthrough, Bydon told ABC News' Will Reeve, who is the director of The Christopher Reeve Foundation, a non-profit foundation "dedicated to curing spinal cord injury," according to its website. The foundation, named in honor of Will Reeve's late father, was not involved in the funding of Bydon's research.

Bydon's research at the Mayo Clinic is a very early Phase 1 study that only includes 10 people and patient response has varied, according to Bydon.

While there is still yet no cure for spinal cord injury, for Chris, the procedure has been a step forward.

I dont know if these are -- are baby steps, or you know, Neil Armstrong steps, he said. But theyre absolutely steps in the right direction.

Follow this link:
Man paralyzed from the neck down walks again thanks to a new medical innovation - ABC News